Early metabolic responses in temozolomide treated low-grade glioma patients

Journal of Neuro-Oncology

Volumn 95, Issue 1, 2009, Pages 87-93

  Wyss, Matthias ^a   Hofer, Silvia ^a   Bruehlmeier, Matthias ^b   Hefti, Martin ^b   Uhlmann, Catrina ^b   Bärtschi, Esther ^b   Buettner, Ulrich Wolf ^b   Roelcke, Ulrich ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

Chemotherapy; Low grade glioma; Positron emission tomography; Temozolomide; Tyrosine

Indexed keywords

TEMOZOLOMIDE;

ADULT; AMINO ACID TRANSPORT; ARTICLE; BLOOD TOXICITY; BRAIN METABOLISM; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; GLIOMA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; FLUORINE RADIOISOTOPES; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TYROSINE; YOUNG ADULT;

EID: 70349327938     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9896-2     Document Type: Article

References (27)

1. Schiff D, Brown PD, Giannini C (2007) Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 69:1366-1373. doi: 10.1212/01.wnl.0000277271.47601.a1
2. Brada M, Viviers L, Abson C et al (2003) Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14:1715-1721. doi: 10.1093/annonc/mdg371
3. Hoang-Xuan K, Capelle L, Kujas M et al (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22:3133-3138. doi: 10.1200/JCO.2004.10.169
4. Kaloshi G, Benouaich-Amiel A, Diakite F et al (2007) Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome. Neurology 68:1831-1836. doi: 10.1212/01.wnl.0000262034.26310.a2
5. Pouratian N, Gasco J, Sherman JH et al (2007) Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol 82:281-288. doi: 10.1007/s11060-006-9280-4
6. Quinn JA, Reardon DA, Friedman AH et al (2003) Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21:646-651. doi: 10.1200/JCO.2003.01.009
7. Macdonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
8. Miyagawa T, Oku T, Uehara H et al (1998) "Facilitated" amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab 18:500-509. doi: 10.1097/00004647-199805000-00005
9. Kleihues P, Louis DN, Scheithauer BW et al (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215-225
10. EORTC (European Organization of Research and Treatment of Cancer) Intergroup study 22033-26033: Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: A phase III study (http://groups.eortc.be/brain/html/ trials.html)
11. Weckesser M, Langen KJ, Rickert CH et al (2005) O-(2-[18F]fluorethyl)-l- tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 32:422-429. doi: 10.1007/s00259-004-1705-8
12. Mikolajczyk K, Szabatin M, Rudnicki P et al (1998) A JAVA environment for medical image data analysis: Initial application for brain PET quantitation. Med Inform (Lond) 23:207-214. doi: 10.3109/ 14639239809001400
13. Wyss MT, Hofer S, Hefti M et al (2007) Spatial heterogeneity of low-grade gliomas at the capillary level: A PET study on tumor blood flow and amino acid uptake. J Nucl Med 48:1047-1052. doi: 10.2967/ jnumed.106.038489
14. Husstedt HW, Sickert M, Kostler H et al (2000) Diagnostic value of the fast-FLAIR sequence in MR imaging of intracranial tumors. Eur Radiol 10:745-752. doi: 10.1007/s003300050997
15. Tang BN, Sadeghi N, Branle F et al (2005) Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol 71:161-168. doi: 10.1007/ s11060-004-9654-4
16. Herholz K, Holzer T, Bauer B et al (1998) 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50:1316-1322
17. Mandonnet E, Delattre JY, Tanguy ML et al (2003) Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53:524-528. doi: 10.1002/ana.10528
18. Ricard D, Kaloshi G, Amiel-Benouaich A et al (2007) Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 61:484-490. doi: 10.1002/ana.21125
19. Ribom D, Schoenmaekers M, Engler H et al (2005) Evaluation of 11C-methionine PET as a surrogate endpoint after treatment of grade 2 gliomas. J Neurooncol 71:325-332. doi: 10.1007/s11060-004-2031-5
20. Nuutinen J, Sonninen P, Lehikoinen P et al (2000) Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 48:43-52. doi: 10.1016/S0360-3016(00)00604-0
21. Voges J, Herholz K, Holzer T et al (1997) 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: A tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact Funct Neurosurg 69:129-135. doi: 10.1159/000099864
22. Asano S, Kameyama M, Oura A et al (2007) L-type amino acid transporter-1 expressed in human astrocytomas, U343MGa. Biol Pharm Bull 30:415-422. doi: 10.1248/bpb.30.415
23. Nawashiro H, Otani N, Shinomiya N et al (2006) l -type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119:484-492. doi: 10.1002/ijc.21866
24. Roelcke U, Radu E, Ametamey S et al (1996) Association of rubidium and C-methionine uptake in brain tumors measured by positron emission tomography. J Neurooncol 27:163-171. doi: 10.1007/BF00177480
25. Wienhard K, Herholz K, Coenen HH et al (1991) Increased amino acid transport into brain tumors measured by PET of l -(2-18F)fluorotyrosine. J Nucl Med 32:1338-1346
26. van den Bent MJ, Kros JM (2007) Predictive and prognostic markers in neuro-oncology. J Neuropathol Exp Neurol 66:1074-1081. doi: 10.1097/ nen.0b013e31815c39f1
27. Yip S, Iafrate AJ, Louis DN (2008) Molecular diagnostic testing in malignant gliomas: A practical update on predictive markers. J Neuropathol Exp Neurol 67:1-15. doi: 10.1097/nen.0b013e31815f65fb